HEPATIC ENCEPHALOPATHY MARKET ANALYSIS

Market News

Global Hepatic Encephalopathy Market: Key Developments

In September, 2022, GENFIT, a late-stage biopharmaceutical company dedicated to improving the lives of patients with liver diseases, announced that they have acquired Clinical-stage Biopharmaceutical company, Versantis, with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE).

On April 7, 2023, Merck, a German multinational science and technology company, and Eisai, a Japanese pharmaceutical company, released information regarding Phase 3 Trials for the treatment of Advanced Melanoma and Metastatic Colorectal Cancer using the orally available multiple receptor tyrosine kinase inhibitors of KEYTRUDA (pembrolizumab) and LENVIMA (lenvatinib) respectively.

On March 3, 2023, Bausch Health Companies Inc. is a Canadian multinational specialty pharmaceutical company, has announced Rifaximin SSD (soluble solid dispersion) tablets plus lactulose is under the clinical trial phase III for treatment of overt hepatic encephalopathy.

Updatesandrecentclinicaltrialsassociatedwith>Hepactivaspssociation upto March,2020 and 24otherupdatesandproductypes. Fallthrough

us-FoodandDrugAdministrationAcceptedANDAtrialsSerimiertialsandas forRethirdpendingsegmentofTrial's.C< pCompanylease.State-MainRealesednews.